Ella Foundation on Monday announced that it has successfully completed preliminary studies to develop a vaccine for the Ebola virus, which has claimed hundreds of lives in West Africa.
The Hyderabad-based foundation said it had completed the preliminary animal experiments of the virus' glycoprotein with the targeted adenovirus.
Claiming that the results of animal experiments were good, Ella Foundation founder director Krishna Ella said these would be followed by pre-clinical toxicology and then clinical trials in humans.
He said Ebola vaccine programme initiated in November last year was an expression of solidarity and the pledge by the Indian prime minister to help the West African nations with their fight against Ebola virus.
According to the World Health Organisation,the current outbreak of Ebola has claimed more than 10,000 lives.
The foundation earlier helped Bharat Biotech to develop of H1N1 pandemic influenza in the early stage.
Ella Foundation, a not-for-profit research organization, is among the two foundations from the Asian region which won the Gates Foundation Grand Challenges Explorations (GCE) grant, an initiative funded by the Bill & Melinda Gates Foundation to foster innovation in global health research.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
